GENITOPE

Serial Number 76178213
Registration 2878198
710

Registration Progress

Application Filed
Dec 8, 2000
Under Examination
Approved for Publication
Oct 17, 2001
Published for Opposition
Nov 6, 2001
Registered
Aug 31, 2004

Trademark Image

GENITOPE

Basic Information

Serial Number
76178213
Registration Number
2878198
Filing Date
December 8, 2000
Registration Date
August 31, 2004
Published for Opposition
November 6, 2001
Cancellation Date
April 1, 2011
Drawing Code
1000

Status Summary

Current Status
Inactive
Status Code
710
Status Date
Apr 1, 2011

Rights Holder

GENITOPE CORPORATION

03
Address
525 Penobscot Drive
Redwood City, CA 94063

Ownership History

GENITOPE CORPORATION

Original Applicant
03
Redwood City, CA

GENITOPE CORPORATION

Owner at Publication
03
Redwood City, CA

GENITOPE CORPORATION

Original Registrant
03
Redwood City, CA

Legal Representation

Attorney
DAVID A. CASIMIR

USPTO Deadlines

Next Deadline
3335 days remaining
Section 8 & 9 (30-Year) Renewal Due (Based on registration date 2004-08-31)
Due Date
August 31, 2034
Grace Period Ends
February 28, 2035

Application History

17 events
Date Code Type Description
Apr 1, 2011 C8.. O CANCELLED SEC. 8 (6-YR)
Mar 28, 2005 COC. O CORRECTION UNDER SECTION 7 - PROCESSED
Dec 6, 2004 MAIL I PAPER RECEIVED
Aug 31, 2004 R.PR A REGISTERED-PRINCIPAL REGISTER
Jun 8, 2004 OP.D T OPPOSITION DISMISSED NO. 999999
Jun 8, 2004 OP.T T OPPOSITION TERMINATED NO. 999999
Jun 8, 2004 OP.T T OPPOSITION TERMINATED NO. 999999
Jun 8, 2004 OP.T T OPPOSITION TERMINATED NO. 999999
Jun 27, 2002 TCAS I TEAS CORR ADDRESS REQUEST RECEIVED BUT NOT PROCESSED STAT IS TTAB
Jun 10, 2002 OP.I T OPPOSITION INSTITUTED NO. 999999
Apr 5, 2002 MAIL I PAPER RECEIVED
Dec 6, 2001 ETOF T EXTENSION OF TIME TO OPPOSE RECEIVED
Nov 6, 2001 PUBO A PUBLISHED FOR OPPOSITION
Oct 17, 2001 NPUB O NOTICE OF PUBLICATION
Apr 24, 2001 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 11, 2001 CNEA F EXAMINER'S AMENDMENT MAILED
Apr 4, 2001 DOCK D ASSIGNED TO EXAMINER

Additional Information

Other
In the statement, column 1, line 5, before Biopharmaceutical, "HOUSE MARK FOR"

USPTO Documents

Loading USPTO documents...